UA78968C2 - Nucleotide sequence for gene therapy of hiv-infected patients by expression of membrane-anchored gp41 peptides - Google Patents
Nucleotide sequence for gene therapy of hiv-infected patients by expression of membrane-anchored gp41 peptides Download PDFInfo
- Publication number
- UA78968C2 UA78968C2 UA2002065189A UA2002065189A UA78968C2 UA 78968 C2 UA78968 C2 UA 78968C2 UA 2002065189 A UA2002065189 A UA 2002065189A UA 2002065189 A UA2002065189 A UA 2002065189A UA 78968 C2 UA78968 C2 UA 78968C2
- Authority
- UA
- Ukraine
- Prior art keywords
- nucleotide sequence
- hiv
- protein
- fact
- vector
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title claims abstract description 30
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 30
- 238000001415 gene therapy Methods 0.000 title claims abstract description 8
- 101800001690 Transmembrane protein gp41 Proteins 0.000 title abstract 3
- 239000013598 vector Substances 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
- 239000012634 fragment Substances 0.000 claims abstract description 19
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 6
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000001177 retroviral effect Effects 0.000 claims description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 238000001890 transfection Methods 0.000 claims description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 2
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 claims description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 102000057074 human RPA1 Human genes 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- 229960001319 parathyroid hormone Drugs 0.000 claims description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 19
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 241000711975 Vesicular stomatitis virus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 1
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 108010055790 immunoglobulin B Proteins 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19957838A DE19957838C2 (de) | 1999-11-25 | 1999-11-25 | Gentherapie von HIV-Infizierten durch Expression von Membran-verankerten gp41-Peptiden |
| PCT/EP2000/011733 WO2001037881A2 (de) | 1999-11-25 | 2000-11-24 | Gentherapie von hiv-infizierten durch expression von membran-verankerten gp41-peptiden |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA78968C2 true UA78968C2 (en) | 2007-05-10 |
Family
ID=7931006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002065189A UA78968C2 (en) | 1999-11-25 | 2000-11-24 | Nucleotide sequence for gene therapy of hiv-infected patients by expression of membrane-anchored gp41 peptides |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7790870B1 (xx) |
| EP (1) | EP1234044B1 (xx) |
| JP (1) | JP2003529339A (xx) |
| KR (1) | KR100840430B1 (xx) |
| CN (1) | CN1425072A (xx) |
| AT (1) | ATE412757T1 (xx) |
| AU (1) | AU3004101A (xx) |
| BR (1) | BR0015942A (xx) |
| CA (1) | CA2392468A1 (xx) |
| CZ (1) | CZ20021764A3 (xx) |
| DE (2) | DE19957838C2 (xx) |
| EA (1) | EA006434B1 (xx) |
| ES (1) | ES2315247T3 (xx) |
| HK (1) | HK1049186B (xx) |
| HU (1) | HUP0203518A2 (xx) |
| NO (1) | NO20022468L (xx) |
| PL (1) | PL358785A1 (xx) |
| SK (1) | SK7132002A3 (xx) |
| UA (1) | UA78968C2 (xx) |
| WO (1) | WO2001037881A2 (xx) |
| ZA (1) | ZA200204710B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10257770A1 (de) * | 2002-12-10 | 2004-07-08 | Ruprecht-Karls-Universität Heidelberg | Expression von Peptiden des zytoplasmatischen Bereiches von HIV-gp41 zur Hemmung viraler Infektionen |
| CA2548483A1 (en) * | 2003-08-26 | 2005-03-10 | Uwe Fiebig | Induction of antiviral neutralizing antibodies in humans and animals |
| WO2005056804A1 (ja) * | 2003-12-11 | 2005-06-23 | Takara Bio Inc. | レセプターの機能の調節方法 |
| GB0422439D0 (en) * | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
| AU2006207181A1 (en) * | 2005-01-24 | 2006-07-27 | Yeda Research & Development Co. Ltd. | HIV-1 gp41 fusion peptides for immunomodulation |
| EP4397748A1 (en) * | 2021-08-30 | 2024-07-10 | Kanglin Biotechnology (Hangzhou) Co., Ltd. | Gene sequence construct for gene therapy for hiv infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935233A (en) * | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5851828A (en) * | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5858744A (en) * | 1994-09-08 | 1999-01-12 | Boehringer Mannheim Gmbh | Retroviral vector hybrids and the use thereof for gene transfer |
| EP0817854A2 (en) * | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
| FR2762851B1 (fr) * | 1997-04-30 | 1999-10-29 | Inst Nat Sante Rech Med | Construction et expression d'enveloppe chimerique de retrovirus par des vecteurs et compositions pharmaceutiques les contenant |
| AU3220500A (en) * | 1999-02-02 | 2000-08-25 | Uab Research Foundation, The | Hiv drug resistance system |
-
1999
- 1999-11-25 DE DE19957838A patent/DE19957838C2/de not_active Expired - Fee Related
-
2000
- 2000-11-24 BR BR0015942-5A patent/BR0015942A/pt not_active Application Discontinuation
- 2000-11-24 US US10/148,064 patent/US7790870B1/en active Active
- 2000-11-24 SK SK713-2002A patent/SK7132002A3/sk not_active Application Discontinuation
- 2000-11-24 EA EA200200598A patent/EA006434B1/ru not_active IP Right Cessation
- 2000-11-24 CZ CZ20021764A patent/CZ20021764A3/cs unknown
- 2000-11-24 CN CN00818655A patent/CN1425072A/zh active Pending
- 2000-11-24 JP JP2001539494A patent/JP2003529339A/ja active Pending
- 2000-11-24 PL PL00358785A patent/PL358785A1/xx not_active Application Discontinuation
- 2000-11-24 ES ES00990613T patent/ES2315247T3/es not_active Expired - Lifetime
- 2000-11-24 KR KR1020027006648A patent/KR100840430B1/ko active IP Right Grant
- 2000-11-24 UA UA2002065189A patent/UA78968C2/uk unknown
- 2000-11-24 HU HU0203518A patent/HUP0203518A2/hu unknown
- 2000-11-24 DE DE50015431T patent/DE50015431D1/de not_active Expired - Lifetime
- 2000-11-24 AU AU30041/01A patent/AU3004101A/en not_active Abandoned
- 2000-11-24 EP EP00990613A patent/EP1234044B1/de not_active Expired - Lifetime
- 2000-11-24 CA CA002392468A patent/CA2392468A1/en not_active Abandoned
- 2000-11-24 AT AT00990613T patent/ATE412757T1/de not_active IP Right Cessation
- 2000-11-24 WO PCT/EP2000/011733 patent/WO2001037881A2/de active Application Filing
-
2002
- 2002-05-24 NO NO20022468A patent/NO20022468L/no not_active Application Discontinuation
- 2002-06-12 ZA ZA200204710A patent/ZA200204710B/xx unknown
-
2003
- 2003-02-24 HK HK03101383.0A patent/HK1049186B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3004101A (en) | 2001-06-04 |
| WO2001037881A2 (de) | 2001-05-31 |
| HK1049186A1 (en) | 2003-05-02 |
| KR100840430B1 (ko) | 2008-06-20 |
| EA200200598A1 (ru) | 2002-12-26 |
| WO2001037881A9 (de) | 2002-11-07 |
| EP1234044A2 (de) | 2002-08-28 |
| SK7132002A3 (en) | 2002-10-08 |
| HK1049186B (zh) | 2009-02-27 |
| KR20020060752A (ko) | 2002-07-18 |
| WO2001037881A3 (de) | 2001-12-13 |
| EA006434B1 (ru) | 2005-12-29 |
| CN1425072A (zh) | 2003-06-18 |
| JP2003529339A (ja) | 2003-10-07 |
| HUP0203518A2 (en) | 2003-02-28 |
| BR0015942A (pt) | 2002-08-27 |
| DE50015431D1 (de) | 2008-12-11 |
| PL358785A1 (en) | 2004-08-23 |
| NO20022468D0 (no) | 2002-05-24 |
| NO20022468L (no) | 2002-07-22 |
| CZ20021764A3 (cs) | 2003-02-12 |
| ATE412757T1 (de) | 2008-11-15 |
| US7790870B1 (en) | 2010-09-07 |
| ZA200204710B (en) | 2003-05-15 |
| DE19957838C2 (de) | 2002-11-21 |
| DE19957838A1 (de) | 2001-06-13 |
| ES2315247T3 (es) | 2009-04-01 |
| CA2392468A1 (en) | 2001-05-31 |
| EP1234044B1 (de) | 2008-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10226538B2 (en) | Methods and compositions relating to improved lentiviral vectors and their applications | |
| CA2148934C (en) | Targetable vector particles | |
| US9260725B2 (en) | Methods and compositions relating to improved lentiviral vector production systems | |
| WO1989005349A1 (en) | Method of combating viral infections | |
| DK175613B1 (da) | Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for AIDS, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet | |
| CN112442514B (zh) | 慢病毒包装载体系统、慢病毒及其构建方法、试剂盒 | |
| EP2078726A1 (en) | Secretable HIV entry inhibitory peptides for therapy of HIV infection | |
| UA78968C2 (en) | Nucleotide sequence for gene therapy of hiv-infected patients by expression of membrane-anchored gp41 peptides | |
| Pfeiffer et al. | Effects of signal peptide exchange on HIV-1 glycoprotein expression and viral infectivity in mammalian cells | |
| CN114478713B (zh) | 一种cmv包膜蛋白包装慢病毒载体及其应用 | |
| US6712612B1 (en) | Safe and stable retroviral helper cell line and related compositions and methods | |
| AU622129B2 (en) | Vector for the expression of proteins of the hiv-2 virus, one of the casual agents of aids, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained | |
| JPH01500962A (ja) | ウィルスベクター及びエイズ原因ウィルスのｆ蛋白質をコードするｄｎａ組換え体、該ベクターにより感染された細胞培養物、上記蛋白質の製造方法、得られた蛋白質、ワクチン及び得られた抗体 | |
| EP0502179A1 (en) | Enhanced expression of viral proteins in drosophila cells | |
| US20060067948A1 (en) | Viral vectors | |
| EP1130089A1 (en) | Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition | |
| HASELTINE et al. | RETROVIRUSES IN HUMAN LYMPHOMA/LEUKEMIA, M. MIWA ET AL.(EDS.), JAPAN SCI. SOC. PRESS, TOKYO/VNU SCIENCE PRESS, UTRECHT, PP. 187-196, 1985 | |
| Harboring | Efficient Gene Delivery to Quiescent Interleukin-2 (IL-2) | |
| AU2002249393A1 (en) | Viral vectors | |
| CA2229515A1 (en) | Expression of a foamy virus envelope protein |